Lumos Pharma, Inc. (LUMO) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Austin, TX, アメリカ. 現CEOは Richard J. Hawkins.
LUMO を有する IPO日 2011-11-11, 30 名の正社員, に上場 NASDAQ Global Market, 時価総額 $37.54M.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
